Contingency planning for U.K. biopharmas to continue after May survives vote

The U.K. life sciences sector avoided further turmoil after a confidence vote in the Conservative party provided Prime Minister Theresa May with near-term political stability, but it did little to improve her odds of getting the current Brexit deal through Parliament. Therefore industry is likely to plow forward with contingency planning for a no-deal scenario.

Association of the British Pharmaceutical Industry CEO Mike Thompson warned in a statement on Monday that a no-deal Brexit "would present very serious challenges and this must be avoided." The BIA declined to comment ahead of the confidence vote, while the ABPI did not respond to a request to comment...